Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 4
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Radiation: radiotherapy combined with EPDrug: radiotherapy / EP combined with recombinant human endostatin
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2010-09-29
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 170
- Registration Number
- NCT01211002
- Locations
- 🇨🇳
Daping Hospital, Chongqin, China
The Effect of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular Carcinoma
Phase 2
- Conditions
- Early Stage Hepatocellular Carcinoma
- Interventions
- Procedure: Radical resection
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2010-01-26
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 250
- Registration Number
- NCT01055743
- Locations
- 🇨🇳
Eastern Hepatobiliary Surgery Hospital, Shanghai, China
A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 4
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: Gemcitabine-Cisplatin chemotherapy
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2009-12-09
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT01028729
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)
Phase 4
- Conditions
- Advanced NSCLCRecurrent NSCLC
- Interventions
- Drug: Endostar(rh recombinant endostatin) plus Docetaxel
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2010-01-25
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 300
- Registration Number
- NCT00813332
- Locations
- 🇨🇳
Cancer Hospital of Tianjin Medical University, Tianjin, China
Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma
Phase 2
- Conditions
- Advanced MelanomaUntreated Patients
- Interventions
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2009-12-08
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 140
- Registration Number
- NCT00813449
- Locations
- 🇨🇳
Beijing tumor hospital, Beijing, Beijing, China
FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer
Phase 2
- Conditions
- Colorectal Neoplasms
- Interventions
- Drug: Folfox4 plus recombinant human endostatin (Endostar)
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2009-12-08
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT00813137
- Locations
- 🇨🇳
The Affiliated Zhongda Hospital of Southeast University, Nanjing, Jiangsu, China
🇨🇳The Affiliated Changzhou Tumor Hospital of Suzhou University, Changzhou, Jiangsu, China
© Copyright 2025. All Rights Reserved by MedPath